Chronic plaque psoriasis is a long-lasting autoimmune skin condition characterized by raised, inflamed, and scaly patches that significantly impact quality of life. According to the International Psoriasis Council, psoriasis affects 2-3% of the global population. Current therapies include biologics, small molecules, and topical agents targeting inflammatory pathways. According to the chronic plaque psoriasis pipeline analysis by Expert Market Research, growing R&D in biologics, personalized treatments, and focus on comorbidity management are expected to drive significant growth in the coming years.
Major companies involved in the chronic plaque psoriasis pipeline analysis include Shanghai Junshi Bioscience Co., Ltd., Livzon Pharmaceutical Group Inc., and others.
Leading drugs currently in the pipeline include JS005, LZM012, ZL-1102, and others.
Pipeline growth in chronic plaque psoriasis will be driven by novel biologics targeting IL-23 and IL-17 pathways, expanding small-molecule therapies, and increasing regulatory approvals supporting treatment diversification.
The Chronic Plaque Psoriasis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into chronic plaque psoriasis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for chronic plaque psoriasis. The chronic plaque psoriasis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The chronic plaque psoriasis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with chronic plaque psoriasis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chronic plaque psoriasis.
Read more about this report - Request a Free Sample
Chronic plaque psoriasis is a long-term autoimmune skin disorder characterized by thick, red, scaly patches caused by an overactive immune response leading to rapid skin cell turnover. It develops due to genetic, immune, and environmental triggers.
Chronic plaque psoriasis treatment includes topical agents, systemic therapies, and biologics targeting cytokines such as interleukin-17, interleukin-23, and tumor necrosis factor-alpha to reduce inflammation and control disease progression. In October 2023, the United States Food and Drug Administration approved Bimekizumab (Bimzelx) for plaque psoriasis. This biologic, targeting both interleukin-17A and interleukin-17F, demonstrated rapid and sustained efficacy in phase 3 trials.
Chronic plaque psoriasis is a widespread, immune-mediated condition affecting an estimated 2–3% of the global population, with higher prevalence in Western countries. According to the International Psoriasis Council, incidence exhibits a bimodal age pattern, peaking between 35–44 and 65–74 years. Early-onset disease is strongly linked to HLA-C*06:02, while late-onset forms involve multiple environmental and genetic factors. Aidar Dairov et al., 2025, report that approximately 125 million people are affected worldwide, with regional prevalence varying significantly, from over 60% in parts of Africa to more than 90% in Asia. About 30% of patients experience joint involvement, and the condition is associated with comorbidities such as obesity, cardiovascular disease, and diabetes, highlighting substantial clinical, psychological, and socioeconomic impact across all age groups.
This section of the report covers the analysis of chronic plaque psoriasis drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The chronic plaque psoriasis pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total chronic plaque psoriasis clinical trials (around 43%) indicating a strong progression toward late-stage development. Phase IV contributes 24%, reflecting ongoing post-marketing studies. Phase II accounts for 19%, and phase I for 12%. This distribution underscores a robust pipeline, with a substantial number of therapies nearing market readiness. The advancements in phase III and IV trials are particularly promising, potentially leading to the introduction of novel treatments that could enhance patient outcomes and address unmet needs in managing chronic plaque psoriasis.
The drug molecule categories covered under the chronic plaque psoriasis pipeline analysis include small molecules, biologics, proteins, and peptides. The chronic plaque psoriasis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for chronic plaque psoriasis. Immune-targeted biologics are a key focus in the chronic plaque psoriasis drug pipeline. For example, YESINTEK™, a biosimilar to Ustekinumab, showed positive Phase 3 results in March 2025 for moderate to severe cases. It functions by selectively inhibiting interleukins IL-12 and IL-23, reducing immune-mediated inflammation. This approach offers patients a cost-effective and clinically equivalent alternative to reference biologics.
The EMR report for the chronic plaque psoriasis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed chronic plaque psoriasis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in chronic plaque psoriasis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for chronic plaque psoriasis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of chronic plaque psoriasis drug candidates.
JS005, developed by Shanghai Junshi Bioscience Co., Ltd., is a recombinant humanized monoclonal antibody targeting IL-17A, designed to reduce inflammation in moderate to severe chronic plaque psoriasis. The ongoing Phase III trial is evaluating its efficacy and safety through a multicenter, randomized, double-blind, placebo-controlled study involving 747 adults. The study is examining clinical improvements, durability of response, and safety outcomes, aiming to establish JS005 as a promising biologic therapy for psoriasis.
LZM012, sponsored by Livzon Pharmaceutical Group Inc., is undergoing a multicenter, randomized, double-blind, Phase III clinical trial to evaluate its efficacy and safety in moderate to severe chronic plaque psoriasis. This innovative dual-target IL-17A/F monoclonal antibody is designed to block both IL-17A and IL-17F cytokines, preventing their interaction with IL-17 receptors. By adopting this dual blockade approach, LZM012 is showing promise in reducing inflammation and inhibiting immune cell migration more effectively than existing IL-17A therapies.
ZL-1102, sponsored by Zai Lab (Hong Kong), Ltd., is under evaluation in a Phase 2 randomized, double-blind, vehicle-controlled study for chronic plaque psoriasis. This novel human VH antibody fragment targets IL-17A and is formulated as a topical gel, aiming to provide a localized therapy for mild-to-moderate cases. The study is examining efficacy, safety, and dose response, while minimizing systemic toxicity compared to conventional systemic anti-IL-17 therapies.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Chronic Plaque Psoriasis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for chronic plaque psoriasis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into chronic plaque psoriasis collaborations, regulatory environments, and potential growth opportunities.
Plaque Psoriasis Treatment Market
Plaque Psoriasis Pipeline Analysis Report
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share